JCO Precis Oncol June 2023 PMID 37315265

Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.

Apar K Ganti, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Elie G Dib, Herbert L Duvivier, Eugene R Ahn, Deepti Behl, Hossein Borghaei, Ani S Balmanoukian, Anu Gaba, Rui Li, Kwabena Osei-Boateng, Ramya Thota, Gina N Grantham

Full text PDF Download social card

Mentions

Peak: 15 in Jun 2023

across 2 sources since Jun 2023

Extended reach

185,084

potential audience

Total likes

Video views

Mentions per month

Jun 2023 – Apr 2024

Where it's discussed

X / Twitter19 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions reflect a generally positive reception, with many posts emphasizing the promising antitumor activity and manageable safety, exemplified by phrases like 'antitumor activity' and 'manageable safety.' Words like 'hot off the press' and mentions of specific study details contribute to an engaged and somewhat optimistic tone, indicating the potential impact of these findings on lung cancer treatment research.

AgreementModerate agreement

Most discussions support the positive findings, highlighting antitumor activity and manageable safety profiles.

InterestModerate interest

Posts show moderate interest by emphasizing key results and the study's significance with phrases like 'hot off the press' and 'manageable safety.'

EngagementModerate engagement

Comments reference specific details such as efficacy rates and safety outcomes, indicating active engagement.

ImpactModerate impact

The discussions suggest the findings could influence future treatments and research directions.

Abstract in brief

The Targeted Agent and Profiling Utilization Registry Study is testing the effectiveness of targeted treatments for advanced lung cancer patients with specific genomic alterations.
The study involved 28 patients, primarily with non-small-cell lung cancer, who received a combination therapy of pertuzumab and trastuzumab, aiming for disease control and measuring various outcomes, including overall survival.
Results indicated a 37% disease control rate, with some patients showing a partial response, though there were also notable serious side effects from the treatment.

Read the full abstract

All mentions

Targeted Therapy with Pertuzumab and Trastuzumab in Lung Cancer Patients with ERBB2 Alterations

Dr. Apar K Ganti discusses the effectiveness of combined Pertuzumab and Trastuzumab therapy in lung cancer patients with ERBB2 mutations or amplifications, highlighting study results and clinical decision-making for…

ASCO Podcasts · Apr 3, 2024 18 views

चंद्रपाल सिंह परिहार

@shailu_par · X

RT @AparGanti: Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Age…

Aug 16, 2023 · 2 shares · 95 followers View post →

Arthi Sridhar

@ASridharMD · X

RT @AparGanti: Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Age…

Aug 15, 2023 · 2 shares · 909 followers View post →

Apar Kishor Ganti

@AparGanti · X

Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study https://t.co/EOoEQ9voHo

Aug 15, 2023 · 7 likes · 2 shares · 259 followers View post →

JCO Precision Oncology

@JCOPO_ASCO · X

.@ASCO #TAPUR Study: Pertuzumab + trastuzumab had antitumor activity and manageable safety in heavily pretreated patients w/ ERBB2-mutated NSCLC.

Jul 5, 2023 · 2 likes · 5,308 followers View post →

JCO Precision Oncology

@JCOPO_ASCO · X

Jun 23, 2023 · 5 likes · 5,308 followers View post →

Pam Mangat-Dhaliwal

@PamMangat2 · X